Targeting Ras with Macromolecules.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Activating mutations in Ras proteins are implicated in approximately 30% of human cancers.
• Ras proteins are challenging drug targets due to their intracellular function and lack of binding pockets for small molecules.

Purpose of the Study:

• To provide an overview of developing macromolecular inhibitors targeting oncogenic Ras mutants.
• To explore various modalities for Ras-targeted anticancer drug discovery.

Main Methods:

• Review of emerging strategies for Ras protein inhibition.
• Analysis of macromolecular inhibitor classes including peptides, macrocycles, antibodies, non-immunoglobulin proteins, and nucleic acids.

Main Results:

• Significant research efforts are focused on developing novel therapeutic approaches against Ras.
• Macromolecular inhibitors offer promising alternatives to conventional small molecules for Ras targeting.

Conclusions:

• Targeting Ras proteins, particularly oncogenic mutants, remains a critical area in cancer therapy.
• Diverse macromolecular strategies are being investigated to overcome the inherent challenges of Ras drug discovery.